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OBSTRUCTIVE SLEEP APNEA AS A RISK FACTOR IN THE DEVELOPMENT                                                  
  OF NONALCOHOLIC FATTY LIVER DISEASE  
  ALEXANDER S. LEE 
 
            ABSTRACT 
Nonalcoholic fatty liver disease (NAFLD) afflicts approximately a quarter of the world’s 
general population and more than half of the world’s obese population. The disease is 
characterized by a spectrum of liver pathologies, ranging from simple steatosis or the 
accumulation of fat within hepatic tissue to steatohepatitis comprised of inflammation 
and fibrosis, also known as NASH. Simple steatosis is relatively asymptomatic and is 
considered benign, but NASH poses great risk for advanced forms of liver disease, such 
as cirrhosis and hepatocellular cancer.  
Obstructive sleep apnea (OSA) is a respiratory disorder involving the recurrent collapse 
of the upper airway during sleep. Consequently, the patient experiences constant arousals 
due to constant blockage followed reopening of the airway. Aside from poor quality and 
disruption of sleep, chronic intermittent hypoxia (CIH) is also present during OSA. The 
presence of CIH leaves many vital organs deprived of adequate oxygen to carry out 
normal physiological function. In response to this hypoxic state, the body upregulates 
many transcription factors, many of which control inflammatory processes.  
In recent studies, chronic and recurrent hypoxia generated from OSA has been implicated 
in the onset and progression of NAFLD. The pathogenesis of NAFLD is believed to be 
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associated with metabolic imbalances, mainly obesity and insulin resistance, both of 
which also overlap with OSA. These conditions are the main factors in predisposing a 
patient suffering from OSA to the effects of CIH. Multiple lines of evidence suggest that 
CIH may accelerate the development of NAFLD through 1) Lipolysis of hepatic adipose 
tissue and increased hepatic free fatty acids; 2) Upregulation of lipid biosynthesis through 
CIH; 3) Upregulation of hypoxia-inducible factor 1-alpha by CIH-inducing liver 
inflammation and fibrosis. 
The primary focus of this thesis will attempt to determine a possible link between OSA 
and NAFLD. Through citation of prior scientific studies, it will formulate the theory of 
OSA as a predisposing factor in the heightened risk of NAFLD pathogenesis and 
development to more severe, terminal stages. Primarily, the review of literature will 
explore the associations of obesity and insulin resistance in relation to OSA and NAFLD. 
Ultimately, deposition of fat and inflammation triggered through various chemical factors 
connected to OSA will be involved in both the generation and progression of NAFLD.  
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INTRODUCTION 
The first section of this thesis will provide brief insight into two diseases affecting 
populations worldwide: Non-alcoholic fatty liver disease (NAFLD) and obstructive sleep 
apnea (OSA). It will outline the main pathological feature of OSA to give a general sense 
of how its presence might incite the onset of NAFLD. In addition, there will be an 
explanation of how two main metabolic disorders, obesity and insulin resistance, serve as 
links between the two diseases. It will touch upon the methods of quantifying the severity 
of the two diseases followed by a short review of literature underlying various factors 
impacting progression of NAFLD through OSA.  
Significance of NAFLD and OSA 
NAFLD has been categorized as the most prevalent chronic liver disease in the world and 
afflicts approximately 30% of the world’s general adult population. Among those 
affected by obesity and diabetes, the prevalence more than doubles, as estimated between 
60% and 70% of adults worldwide (1). The implications for NAFLD include not only 
patient mortality resulting from later stages of the disease, but also heightened costs in 
healthcare, as deduced from a 5-year follow up study in which NALFD patients were 
burdened with a 26% increase in overall healthcare costs (2). Also related to healthcare 
costs, NAFLD also has the potential to become the most common cause for liver 
transplantation by 2020 (3), which will have several implications on the availability of 
liver donors for NAFLD patients. Therefore, future concerns in healthcare should attempt 
to curb these staggering increases by informing patients about preventative measures 
against liver disease, as will be discussed with OSA further on.  
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NAFLD is defined across a histological spectrum, ranging from the most “mild” stage of 
simple steatosis to the most severe form of the disease, steatosis plus necro-inflammation, 
more commonly known as non-alcoholic steatohepatitis, NASH. Moreover, NASH can 
lead to increasingly severe liver-related complications including cirrhosis, the irreversible 
scarring of liver tissue, as well as hepatocellular carcinoma (4). In both cases, the blood 
flow through the liver is greatly impeded and the detoxifying function of the liver is 
impaired. The deterioration of the liver as a vital organ due to terminal pathologies of 
NAFLD often results in patient death. 
On the other hand, obstructive sleep apnea (OSA) is a disorder affecting more than 4% of 
the general population, with that number rising to 35-45% in obese individuals (5) (6). 
During periods of sleep, OSA patients suffer from collapse of their upper airway, 
resulting from decreased pharyngeal patency. The blockade of air flow then presents 
many health concerns, mainly from the attenuated oxygen saturation and thus lower 
oxygen levels in vital organs.  
Aside from snoring that can be disruptive to family members and excessive daytime 
sleepiness, the hypoxia stemming from stoppages of air flow during sleep trigger various 
metabolic processes. These physiological changes attempt to compensate for reduced 
oxygen, but also set into motion several cellular modifications that lead to the 
developments of various diseases, such as NAFLD.  
The Potential of CIH for Induction of Liver Pathology 
The key feature of obstructive sleep apnea responsible for pathogenesis NAFLD is 
chronic intermittent hypoxia (CIH). As will be the later focus this thesis, CIH is 
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responsible for inducing various alterations at the molecular level, which occur through 
oxidative stress, perpetuated systemic inflammation, and elevated sympathetic activity 
(7). In terms of NAFLD, these cellular processes occur upstream of pathological changes 
in hepatic tissue that culminate in various forms of liver disease. 
CIH occurs as result of changes regarding anatomic abnormalities of the pharynx. Sleep 
disorder begins with the inability of upper airway muscles, which include the 
genioglossus and tensor palatine muscles, to sufficiently dilate (7). Consequently, this 
leads to continuous pharyngeal collapse. This event corresponds with the narrowing of 
the airway oxygen intake. Physiologically, the body senses the apneic events in the form 
of falling oxygen saturation levels as well as increases in the partial pressure of carbon 
dioxide in the arterial blood. These chemical changes are relayed by the carotid body, 
which are chemoreceptors situated near the bifurcation of the carotid artery running along 
either side of the throat.  
Information sensed by the carotid body projects to the central nervous system along the 
carotid sinus branch of the glossopharyngeal nerve, eventually terminating in the nucleus 
of the solitary tract (NST). As a compensatory measure to restore pharyngeal patency and 
adequate breathing, the body relies on the arousal system, neurological pathways 
hypothesized to be in either the basal forebrain or the pre-locus coeruleus region of the 
brain stem. The function of the arousal system is to induce a brief awakening from sleep 
or a cortical arousal (8). However, this only serves as a temporary solution and does not 
solve the recurring issue of hypoxia, generated from perpetuated cycles of falling asleep 
and awakening. Therefore, nothing prevents the airway from collapsing again and 
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preventing inhalation, as well as the arousal system from triggering cortical arousals and 
so forth.  
Ultimately, the constant cycling between collapsed and reopened airway corroborates 
with chronic cycles of desaturation-reoxygenation. These transient hypoxic states result 
in two major physiological changes that will contribute to the onset of NAFLD. One such 
changes involves the increased levels of reactive oxygen species (ROS) that prompt 
regulation of cell adhesion and migratory processes, leukocyte recruitment, and activation 
of inflammatory processes (8). The other includes intensified sympathetic nervous system 
activity as an adaptive response to the circulatory and ventilatory changes brought on by 
CIH. It is the interaction between upregulation of the sympathetic nervous system and the 
incitement of oxidative stress and inflammatory processes that underlie the metabolic 
consequences of OSA, including the pathogenesis of NAFLD.  
Obesity and Insulin Resistance as Predisposing Factors 
While chronic intermittent hypoxia serves as the main aggravating factor in the 
development of liver disease, there are two metabolic conditions that predispose OSA 
patients to NAFLD, which are obesity and insulin resistance. As both are strongly 
associated with the two diseases, a brief understanding of their relation to OSA and 
NAFLD will be provided, as their importance in linking the two diseases will be repeated 
throughout the thesis.  
Among many OSA patients, obesity often accompanies obstructive sleep apnea. The 
reasoning behind this is related to fat distribution surrounding the airway. In obese OSA 
patients, the tube of the pharyngeal airway is more susceptible to collapse because of 
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excessive fat deposition in two specific areas (9). The first area of fat accumulation is the 
pharyngeal airway region, which can be divided into the retropalatal region and 
retroglossal region (10).  Increases in fat tissue volume around these two areas cause an 
upper airway anatomical imbalance. This constricts the tube due to increases in the 
surrounding tissue pressure, contributing to a narrowed airway. The other region of fat 
deposition contributing to an obstructed airway is around the lung, mainly caused by 
excess visceral fat. The surplus of abdominal fat decreases the chest wall and diaphragm 
movement, resulting in compression of the lung and decreasing its volume. Subsequently, 
these alterations reduce chest compliance and functional residual capacity that generate 
longitudinal tracheal traction forces and pharyngeal wall tension. Ultimately, this 
produces the same effect of narrowing the airway and oxygen inflow.  
In addition, obesity also contributes to the progression of nonalcoholic fatty liver disease. 
However, as opposed to having a more direct effect, such as in OSA, obesity mediates 
damage to the liver in conjunction of another metabolic disorder, insulin resistance. (11) 
Excessive weight gain as a major feature of obesity is responsible not only for the 
obstruction of the airway among OSA patients, but also for impairment of insulin 
sensitivity. Once a patient reaches a certain threshold in weight, the corresponding excess 
adipose tissue begins releasing heightened levels of non-esterified fatty acids, glycerol, 
hormones, and pro-inflammatory cytokines that collectively disrupt the function of β-
pancreatic cells in secreting insulin (12). The lower circulating levels of insulin are 
insufficient to trigger responses in target tissues, among them the liver, which is now 
resistant to the antilipolytic effects of insulin (12). Without any inhibition, uncontrolled 
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hydrolysis of hepatic triglycerides leads to a free fatty acid (FFA) flux within the liver. 
The increase in FFAs is accompanied by the simultaneous and paradoxical upregulation 
of triglyceride synthesis due to increased lipolysis coupled with excessive fat intake. The 
process is summarized in Figure 1. The subsequent fat accumulation within hepatocytes 
marks the beginning of NAFLD as simple steatosis, which can then progress to more 
malevolent disease forms along the spectrum when incited by inflammatory factors.  
 
Figure 1.  Potential Sources of Fat Accumulation Induced by Insulin Resistance. 
Insulin resistance contributes to NAFLD directly by increasing de novo lipogenesis and 
indirectly by increasing FFA flux to the liver via increased inhibition of lipolysis. Figure 
taken from Utzschneider and Kahn, 2006 (12).  
 
Likewise, insulin resistance serves as another link between OSA as a causative factor of 
NAFLD. OSA is hypothesized to induce metabolic changes that lead to rises in insulin 
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resistance (11), which will be supported by experimental studies presented later in this 
thesis. The hypoxic cellular state brought on by intermittent deprivation of oxygen from 
obstructed airways is what accounts for the noticeable drop in insulin sensitivity (Figure 
2). The physiological basis for OSA inducing insulin resistance can be traced back to a 
disruption in the sleep cycle, which is divided into two electroencephalographic stages 
(13). The relevant stage regarding OSA is the non-rapid eye movement stage (NREM). 
After intervals of 60 to 90 minutes, a person normally enters the other stage of the sleep 
cycle, rapid eye movement (REM) (13). However, OSA patients often fail to reach the 
REM stage because of an obstructed airway inducing constant arousals from sleep. 
Rather, their sleep cycles are reset with each awakening from sleep, unable to advance 
from the NREM stage.  
This perpetuated state of NREM is problematic due to the various hormonal changes 
responsible for growth and repair that normally take place during this time. One of the 
hormones secreted in greater amounts during NREM sleep compared to the wakeful state 
is growth hormone (GH) (14). Although studies have suggested GH can improve the 
histology of NAFLD, the opposite may occur in the presence of OSA. This is because the 
excess growth hormone is what ultimately incites insulin resistance in OSA patients, 
blocking insulin signaling by interfering with signaling molecules such as insulin 
receptor substrate-1 and PI3K, essential for glucose transport (15). Thus, the resulting 
insulin resistance resulting from OSA has the same effect as that caused by obesity, 
another words the accumulation of fat within hepatic tissues and eventually, the 
inflammation of cells within the liver. 
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Figure 2. Mechanisms of Insulin Resistance as Induced by OSA. CIH mediates 
various biological pathways through which OSA can induce abnormal glucose 
homeostasis and the metabolic imbalance of insulin resistance. Figure taken from Doumit 
and Prasad, 2016 (16). 
 
Quantifying Severity of OSA and Categorizing Liver Pathology 
Among the literature for OSA, the severity of obstructive sleep apnea is classified by the 
number of times that diminished respiratory events occur per hour (h-1) within the apnea-
hypopnea index (AHI). The apnea events are characterized as events when the patient has 
cessations in breathing (apneas) that last at least 10 seconds in duration, while hypopnea 
events are characterized as extremely shallow breathing that result in lowered respiratory 
rate (17). Non-OSA patients have an AHI of less than 5 h-1, while patients with severe 
OSA would be described as having an AHI of 30 h-1 (17). In addition, severity of OSA 
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can also be expressed through the respiratory disturbance index (RDI), which is similar to 
AHI and includes apneas and hypopneas, in addition to respiratory-effort related 
arousals (RERAs), other events that also disrupt sleep (18). Severely afflicted OSA 
patients can be categorized as having an RDI of greater than 15 h-1.  
On the other hand, severity of liver histology is qualitatively classified across the 
spectrum of NAFLD and any resulting histopathologic abnormalities. The spectrum 
ranges from the excessive retention of lipids within hepatocytes (simple steatosis) to the 
inflammation of hypertrophic hepatocytes (steatohepatitis), to liver fibrosis, which itself 
can be further divided across various stages, most notably advanced fibrosis (stages 3-4), 
and finally hepatocellular carcinoma (3). Specifically, the degree of liver disease 
increases prognosis of NAFLD and thus itself can be used as a classification for severe 
liver disease (19). The gold standard for diagnosing the presence and severity of NAFLD 
is tissue biopsy, which is accomplished by administering a needle between two of the 
right lower ribs and extracting a liver tissue sample. In the laboratory, the sample is then 
observed under a microscope to gain insight on the degree of inflammation and other 
forms of liver damage.  
In terms of quantitatively characterizing severity of NAFLD, there are no specific or 
sensitive biochemical markers detecting liver pathology. Instead, this is monitored by 
measuring levels of either alanine amino-transferase (ALT) or alanine amino-transferase 
(AST) (20). However, using ALT or AST concentrations to deduce the severity of 
NAFLD can be misleading and therefore may or may not reflect the actual disease 
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progression. Thus, testing for and detecting the presence of OSA may be preventative for 
the early onset of NAFLD.  Potentially, treating OSA as a causative factor for NAFLD 
can assist in the medical challenge of mass screening for significant liver injury during 
the ongoing epidemic of obesity.  
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Main Emphases 
This thesis will explore the causative properties of OSA in the pathogenesis of NAFLD 
and stages along the NAFLD spectrum while attempting to formulate a response 
regarding the validity of this relationship.  
Based on the evidence gathered from the literature, the main emphases of the thesis will 
be as follows: 
1. Explain the underlying relationship between OSA and NAFLD. 
2. Describe the causative mechanisms linking OSA and NAFLD, both direct and 
inferred. 
3. Drawing a conclusion on the viability of OSA as a risk factor for NAFLD. 
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MEDICAL CONDITIONS LINKING OSA AND NAFLD 
CIH as an Instigator of Liver Pathology 
The hypothesis of OSA as a causative factor for early stage NAFLD has been gaining 
traction in recent years. Along with additional factors of obesity and insulin resistance, 
studies have demonstrated a correlation between the generation of intermittent airflow 
and the pathogenesis of liver disease. For example, in an animal model conducted by 
Savransky et al, two groups of mice on the same diets were exposed to either chronic 
intermittent hypoxia (CIH) or intermittent air (IA). Within the CIH group, an increase in 
liver injury was observed along with an increase in serum ALT, 224 ± 39 U/ L as 
compared to the IA group, 118±22 U/L (21). The CIH group was characterized by 
increased hyperglycemia and lipid peroxidation of liver tissue, as well as an upregulation 
of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), often 
associated with liver inflammation. As a corollary, it was noted that OSA via CIH would 
trigger these same conditions and biochemical markers (21).  
Although absent from the aforementioned study, the authors also referred to another CIH-
upregulated chemical factor: tumor necrosis factor-α (TNF-α). TNF- α is significant due 
to functioning as a pro-inflammatory factor, which as demonstrated further in the thesis 
will serve as a hallmark for the detection of NASH when induced by inflammation of 
liver cells.  
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Interaction Between CIH and Obesity in Generating NAFLD 
Savransky et al undertook a similar experiment to their original study of CIH exposure. 
However, this time they modified the diet of the mice and provided them with a high-fat, 
high-cholesterol diet to simulate the condition of obesity (21). In this experiment, liver 
damage among the “fatty” mice as measured by heightened serum ALT (461±58 U/L vs 
103±16 U/L in the control group) was elevated compared to the “non-fatty” mice (224 ± 
39 U/ L) (21). In addition, the authors noted from their modified experiment the presence 
of inflammation and fibrosis within the liver that was not observed among the control 
group. These findings were accompanied by the presence of inflammatory factors such as 
cytokines interleukin-1β, interleukin-6, chemokine macrophage inflammatory protein-2, 
and increases in the levels of TNF-α and in α1 (I)-collagen mRNA, all of which may 
contribute to inflammation within fatty liver cells (22). Thus, when combined with a 
high-fat diet, hypoxia resulting from OSA catalyzes the inflammatory progression of 
NASH from NAFLD.  
Although it is well known that insulin resistance and obesity predispose patients to 
NASH, the exact mechanisms by which this occurs are not well understood. These trends 
can be attributed to the regulation of certain lipogenic genes. Essentially, hypoxia 
dampens insulin sensitivity in affected patients and leads to the upregulation of lipogenic 
genes, among them sterol-regulatory-element-binding protein-1c (SREBP-1c), 
peroxisome proliferator activated receptor-γ (PPAR-γ), acetyl- CoA carboxylase 1 
(ACC1) and acetyl-CoA carboxylase 2 (ACC2) (23). The increased expression of 
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lipogenic genes is followed by a downregulation of genes regulating mitochondrial beta 
oxidation, such as PPAR-α and carnitine palmitoyltransferase-1 (CPT-1) (23). Following 
these modifications in gene activity, there is an uptick in lipogenesis as well as a 
reduction in fat oxidation, which then generates a hepatic environment stimulating fat 
accumulation. In combination with the already excessive fat stores that characterize obese 
patients, OSA acting through the increased expression of lipogenic factors would thus 
influence development of NAFLD to NASH.  
In addition, by stimulating lipolysis and preventing metabolism of FFA, hypoxia creates 
an environment with elevated FFA levels in obese patients. Yin et al hypothesize the 
FFA increase is due to hypoxia directly inhibiting fatty acid transporters (fatty acid 
transport protein-1, FATP1 and fatty acid translocase (FAT) and a transcription factor, 
peroxisome proliferator-activated receptor gamma (PPAR-γ), which regulates fatty acid 
storage and glucose metabolism (24). 
Moreover, OSA has been shown to influence levels of biomarkers indicating liver 
pathology. Specifically, levels of alanine aminotransferase and aspartate aminotransferase 
are affected by the presence of OSA within obese patients. For example, one study 
conducted by Chin et al, measured the ALT and AST concentrations of 44 obese patients 
with OSA, 14 or 35% of which had an increase in liver enzyme concentration as opposed 
to control groups without OSA (25). The authors also noted that treatment of OSA 
alleviated liver pathology For example, one commonly used treatment for OSA, 
continuous positive air pressure (CPAP) therapy, was shown to decrease ALT and AST 
concentrations. The potency of CPAP will be explored in further detail later in the thesis.   
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Although CIH is the main driving force through which OSA influences NAFLD 
development, obesity is also involved in the process by lowering oxygen levels. Two key 
features of obesity, expanded subcutaneous fat and visceral fat have been implicated in 
the progression to potential liver disease. In the obese state, hypertrophic adipose tissue 
produces and releases various pro-inflammatory factors (26). The adipocyte presents 
multiple responses to cell hypertrophy. Among these include the impaired diffusion of 
oxygen within the cell, reduced oxygen supply due to decreases in capillary density, and 
decreased oxygen consumption in adipocytes, possibly due to uncoupled respiration 
resulting from free-fatty acids (26). The pro-inflammatory factors triggered by obesity 
include cytokines such as TNFα, adipokines including leptin. Along with T-cells, these 
chemical factors account for the initial inflammatory state in obese patients that are 
involved in the progression to NASH.  
When accounting for this alternate source of hypoxia, it becomes clear that obesity is not 
just a predisposition for OSA, but works in synergy regarding the inflammation of 
hepatic adipose tissue. Obesity-induced hypoxia and OSA-induced hypoxia feed into one 
another and create a positive feedback loop, with the hepatic adipocytes becoming larger 
and more inflamed as the liver tissue becomes increasingly oxygen starved, releasing 
additional inflammatory factors that begin the cycle anew. Moreover, shortages of 
oxygen also create dysfunction in homeostasis and lipid metabolism, further contributing 
to the enlargement of adipocytes within the liver. Thus, several obesity-related forces are 
responsible for perpetuating the inflammation of liver cells characterizing NASH 
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progression.   
Interaction Between CIH and Insulin Resistance 
Aside from obesity, insulin resistance is the other main metabolic condition connecting 
OSA to the onset of NAFLD. Insulin resistance has been strongly correlated with OSA 
via clinical and experimental studies, by way of exorbitant hepatic triglyceride 
deposition, which is indicative of the simple steatosis stage along the NAFLD spectrum 
(27). One such study by Vgontzas et al utilized experimental analysis consisting of 14 
obese patients with OSA, who displayed increases in TNF-α and IL-6, two inflammatory 
factors that drive the progression of simple steatosis to steatohepatitis (28). This same 
study also reported a greater degree of insulin resistance among the OSA patients with 
apneas than in the control group of patients without sleep disorders. The trend again 
stresses the importance OSA in association with not only with insulin resistance, but also 
inflammation. 
Experiments have also implicated intermittent hypoxia as inducing progression of 
NAFLD beyond the simple steatosis stage in the presence of insulin resistance. Animal 
studies conducted by Tasali and Ip, using obese mice as subjects, have shown that short 
term intermittent hypoxia decreases blood glucose levels as well as increased serum 
insulin levels. Specifically, these mice were exposed to IH over a 12-week period and 
displayed a time-dependent increase in fasting serum insulin levels, initially measured at 
3.6 ± 1.1 ng/mL, which rose to 9.8 ± 1.8 ng/mL by the end of week 12 (29). The mice 
also displayed lowered glucose tolerance, consistent with greater insulin resistance. The 
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study also included a group of lean mice exposed to IH for a 5-day period. While the 
same alterations in metabolism were not observed among these lean mice compared to 
the obese mice, IH did cause significant insulin resistance. Collectively, the studies allude 
to the combination of obesity and/or insulin resistance with OSA contributing to the 
development of NAFLD and eventually progression to NASH. 
 
Furthermore, there are several proposed mechanisms by which OSA may potentiate 
insulin resistance and subsequently, contribute to the inflammation that furthers 
progression of NAFLD. One such process, adipose tissue hypoxia (ATH), may explain 
the circumstance of insulin resistance induced by OSA and inflammation often seen with 
liver disease. In this situation, hypoxia inhibits adipogenesis and triglyceride synthesis, 
thus resulting in an increase of FFA concentration without formation of new adipocytes 
and storage of macromolecules (20). This rise in FFA concentrations also signifies a state 
of morbid obesity which may be linked to ATH and adipocyte death, provoking 
inflammation, which ultimately leads to NASH and other advanced stages of liver 
disease. The method through which morbid obesity induces adipocyte death is unclear, 
but it may be due to a decreased blood flow to adipocytes brought about by obesity-
related vasoconstriction or abated angiogenesis (30).  
The Generation of Inflammation by Hypoxia 
Inflammation is arguably the most prominent mechanism connecting OSA and NAFLD 
and is strongly connected with insulin resistance. In addition, inflammation is also 
responsible for inciting hypertension and abnormal levels of serum lipids present in OSA, 
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which contribute to the aggravation of enlarged hepatocytes (31). One transcription 
factor, NF-κB, is involved not only in inflammatory pathways, but also in obesity and 
OSA, given its upregulation by CIH. This is of significance, because increased levels of 
NF-κB during these medical disorders may explain their involvement in the progression 
of NAFLD.  
Expression of NF-κB then leads to the release of previously mentioned inflammatory 
factors such as TNF-α, IL-1, and IL-6, among others factors such as monocyte 
chemoattractant protein-1, macrophage migration-inhibition factor, inducible nitric oxide 
synthase and matrix metalloproteinase 9, which will be important in the discussion of 
fibrosis further on (20). The heightened levels of TNF-α and IL-1 are also supported by 
previous studies in which OSA and obesity, independently of each other, were also found 
to be increased compared to baseline (32). Moreover, TNF-α and IL-1 are associated with 
increased insulin resistance, further strengthening this relationship. TNF-α and IL-1 as 
mediators of inflammation are also activated by hypoxia-inducible factor (HIF), which is 
a transcription factor released in an oxygen-deprived cellular environment caused by 
hypoxia and will be the focus of later sections in this thesis (29).  
Modification of several transcription factors (Figure 3) is yet another possible 
determinant in generating insulin resistance and the eventual progression from NAFLD to 
NASH. It has been known that hypoxia stimulates SREBP-1c, which has the function of 
binding to the promoter region (sterol regulatory element-1, SRE-1) of two genes, acetyl-
CoA carboxylase(ACC) and fatty acid synthase (FAS) (33). The significance of these 
genes and their activation by SREBP-1c is their role in promoting generation of a fatty 
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liver. Specifically, the two genes code for enzymes involved in lipogenesis, which can 
lead to a buildup of triglycerides, especially the accumulation of fat within hepatocytes 
(34). Likewise, studies have demonstrated that fatty liver induced by hypoxia is 
correlated with an increase in the expression of SREBP-1c. This is reinforced in studies 
of genetically modified insulin-resistant mice, which are characterized with upregulated 
expression of SREBP-1c and the eventual development of fatty livers (33). Thus, the 
abnormal upregulation of SREBP-1c when activated by hypoxia strongly presents a case 
for progression from early-stage NAFLD to NASH.  
A second transcription factor involved in OSA-driven progression of NAFLD is PPAR-γ. 
It mainly functions in regulating fatty acid storage by upregulating genes stimulating lipid 
uptake, adipogenesis, and the responsiveness of pancreatic-β-cells to insulin. When 
expression of PPAR-γ is inhibited, as it seemingly is when the body is exposed to 
hypoxia and the associated upregulation of inflammatory factors NF-κB, TNF-α, IL-1 
and IL-6, there are multiple metabolic abnormalities that occur (36). One of them 
includes hyperlipidemia, which leads to a severe buildup of triglycerides within the liver 
that incites pathogenesis of NAFLD. Another is loss of insulin sensitivity due to 
heightened serum glucose, which as mentioned prior, can also lead to development of 
NAFLD. In addition, excessive upregulation of PPAR-γ in hepatocytes results in lipid 
accumulation within the liver while accounting for hypoxia-induced NAFLD.  
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Figure 3. Upregulation of NASH-related transcription factors by IH. OSA induces a 
buildup of fat within the liver and then accelerates inflammatory processes as mediated 
through IH increasing the expression of HIF and NF-κB. Consequently, this leads to the 
inflammation of accumulated fat within the liver, signifying progression from simple 
steatosis to NASH. Figure taken from Mirrakhimov and Polotsky, 2012 (35). 
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Another subset of PPAR, PPAR- α, is correspondingly downregulated in an oxygen-
deprived body environment and more importantly, its expression is reduced within the 
liver. In the absence of functioning PPAR- α, subsequently there is greatly reduced ability 
of hepatic mitochondria to carry out beta oxidation of fatty acids (36). Subsequently, 
dietary triglycerides, de novo-synthesized triglycerides, and free fatty acids all contribute 
to a buildup of triglycerides within the liver, ultimately resulting in steatosis of 
hepatocytes. As with PPAR-γ, Svegliati-Baroni et al reinforced the significance of 
PPAR- α inducing NAFLD when they characterize PPAR- α-knockout mice as 
developing NAFLD and insulin resistance (36). 
 
 
 
 
Intermittent 
Hypoxia 
 
 
 
 
 
 
 
Figure 4. Downregulation of PPAR isoforms in the presence of intermittent hypoxia. 
Peroxisome proliferator-activated receptor isoform activity act as countermeasures 
against the development and progression of NAFLD.  Inhibition of PPAR-alpha 
activation prevents transcription of CPT-1, a component of beta-oxidation allowing free 
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fatty acids to reach the mitochondrial matrix; Inhibition of PPAR-beta/delta activation 
prevents FOXO-1 transcription, resulting in increased hepatic gluconeogenesis and 
hepatic glucose production; Activation of PPAR-gamma, upregulates SREBP-1c, 
ultimately resulting in increased lipogenesis. Thus, these three processes contribute to the 
pathogenesis of NAFLD. Figure taken from Souza-Mello, 2015 (97). 
 
Another gene of interest, carnitine palmitoyltransferase I (CPT-1) also leads to pathology 
in gene-deficient models. The CPT-1 gene codes for a mitochondrial enzyme acting on 
the outer mitochondrial wall and is essential for transporting fatty acids into the 
mitochondrial matrix for beta-oxidation. In the absence of CPT-1, free fatty acids do not 
reach their intended destination and subsequently elevated FFAs levels within liver cells 
contribute to NAFLD development (37).  
Furthermore, hypoxia also regulates the AMP-activated protein kinase (AMPK) gene, 
which is involved in oxidation of hepatic fatty acids. Regarding NAFLD, AMPK is 
relevant as an inhibitor to SREBP-1C (38). Thus, with abnormally low expression of 
AMPK, there is increased expression of SBREP-1C followed by increased activity of 
lipogenesis, resulting in excessive deposition of fat within the liver and signifying the 
onset of NAFLD.  
Certain cytokines that are secreted by adipose tissue, also known as adipokines, have 
been regarded in the development of NAFLD. Two in particular, adiponectin and leptin, 
have been most closely associated with OSA as a predisposing factor to NAFLD. For 
example, in a study carried out by Savvidou et al, it was determined that low serum levels 
of adiponectin corresponded with progression of NAFLD, specifically to advanced 
hepatic fibrosis (39). Also, several metabolic conditions that have been closely associated 
with NAFLD such as obesity and insulin resistance, appear to be related to declines in 
23 
 
adiponectin levels (40). Additional studies further support these findings, as two different 
experimental investigations by Hosogai et al and Chen et al have demonstrated that the 
occurrence of hypoxia downregulates adiponectin expression in adipocytes (41) (42).  
This negates the protective effects of adiponectin by preventing stimulation of mediators 
involved in the beta oxidation of fatty acids such as AMPK and PPAR-γ. It also removes 
the suppression of inflammatory mediators such as IL-6 and TNF-α, as shown in Figure 
5 (43). Moreover, due to TNF-α inhibiting adiponectin adipocytes (44), hypoxia can be 
described as lowering levels of adiponectin through TNF-α since it contributes to raised 
TNF-α levels and the onset of NASH.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Hypoxia-regulated cytokines. Hypoxia affects the balance of pro- and anti-
inflammatory cytokines secreted by adipose tissue. Hypoxia also decreases the 
concentration of hepatic adiponectin, while increasing the concentration of TNF-α and 
IL-6, subsequently resulting in higher levels of pro-inflammatory cytokines, which is 
associated with NAFLD progression to NASH. Figure taken from Auguet al, 2014 (45).  
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The other adipokine of interest, leptin, is involved regulating energy balance, mainly by 
suppressing hunger and creating a feeling of satiety. Its involvement in NAFLD 
development is demonstrated in a study undertaken by Synder et al in which participants 
were exposed to 17 hours of hypoxia and consequently exhibited elevated levels of serum 
leptin (46). As a corollary, they found that by decreasing oxygen saturation levels, or in 
other words increasing the severity of hypoxia, there was a proportionate increase in 
hepatic inflammation and damage. In pertinence to NAFLD, increased levels of serum 
leptin have also been correlated with severity of liver pathology, specifically the degree 
of inflammation and fibrosis (25).  
Treatment Methods of OSA Improve Pathology of NAFLD  
The association between OSA and NAFLD is demonstrated not only in factors inducing 
pathology, but also through treatment methods that attenuate both diseases and restore 
health and metabolic balance. For instance, alleviating the condition of intermittent 
hypoxia resulting OSA has the effect of greatly reducing its severity. Treatment would in 
theory also have similar outcomes for NAFLD, under assumption of the former being a 
causative risk factor for the latter. For example, CPAP, the most common form of OSA 
therapy, potentially has mitigating effects on NAFLD pathogenesis (25). In theory, CPAP 
reduces the effect of factors such as heightened blood pressure, lipid levels, and insulin 
resistance brought upon by intermittent hypoxia. The effects of CPAP as an indirect 
treatment for NAFLD are demonstrated in separate studies by Chin et al and 
Kheirandish-Gozal (25) (47).  
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The authors Chin et al observed 40 obese patients who were also afflicted with OSA. 
Development of NAFLD was measured by concentrations of liver enzymes, ALT and 
AST. The patients’ ALT, AST, triglyceride, insulin, and leptin levels were measured over 
a period of six months each day. It began by measuring serum levels during the afternoon 
and then again, the following morning after a night’s sleep using nasal CPAP, repeating 
again the following afternoon. Prior to the first administration of CPAP, 14 or 35% of the 
40 patients displayed abnormalities in aminotransferase levels, specifically more than 1.5 
times the upper limit of normal AST levels, defined as greater than or equal to 49 IU/L. 
Among these 14 patients, there were notable increases in AST levels, which were as 
measured presleep, 34 ± 20 IU/L, and postsleep, 39 ± 28 IU/L (25). Compared to these 14 
patients, the remaining 26 patients whose AST levels were within the upper limit had 
lower increases in AST level overnight. Moreover, the 14 patients with elevated AST 
levels were also more likely to have insulin resistance. Thus, insulin resistance within 
these patients correlates with elevated aminotransferase levels and is consistent with the 
pattern of insulin resistance having close association with NAFLD.  
After the first night of CPAP, trends in aminotransferase levels had already begun to 
reverse, with AST levels reverting presleep to postsleep, from 39 ± 28 IU/L to 34 ± 24 
IU/L. ALT levels remained constant, measured 61 ± 53 IU/L and 61 ± 48 IU/L, presleep 
and postsleep, respectively. In addition, leptin serum levels decreased, dropping from 22 
± 13 ng/mL in the morning, pre-CPAP, to 17 ± 10 ng/mL the next morning (25). In 
contrast, insulin resistance, measured by the homeostatic model assessment (HOMA, 
defined as HOMA-IR= (Glucose*Insulin/405, glucose measured in mg/dL)), changed 
26 
 
from 3.4 ± 2.2 to 3.2 ± 16. Similarly, serum triglycerides remained the same, measured 
presleep, 216 ± 103 mg/dL, and then postsleep, 206 ± 128 mg/dL (25). Therefore, in the 
short term, even a single night of CPAP therapy has beneficial effects in reducing 
NAFLD-inducing factors such as pro-inflammatory leptin, determined by reductions in 
liver enzyme concentrations. This further reinforces the association between recurrent 
apnea/hypopnea accompanied by intermittent hypoxia and liver pathology. 
 
In further reports, Chin et al carried out one-month and six-month follow-ups of CPAP 
treatment, which represent the long-term results of OSA therapy as an indirect treatment 
of NAFLD. Patients returned for evaluation after a month of home CPAP therapy, 
wearing a nasal mask during sleep for 4.3 ± 1.4 hours per night. The downward trajectory 
in AST and ALT levels continued, suggesting improvements in liver pathology, as 
reflected in levels of amino aspartate aminotransferase decreased from 39 ± 28 IU/L to 34 
± 24 IU/L, and alanine aminotransferase from 61 ± 53 IU/L to 61 ± 48 IU/L. Moreover, 
there were notable changes in the body mass index in 21 out of 34 of the follow-up 
patients, decreasing from 30.1 ± 4.4 kg/m2 to 29.2 ± 4.1 kg/m2 (25). The authors did not 
specify any biological mechanism induced by CPAP therapy might cause this decrease in 
body mass index. The correlation may be explained by the patients being more 
conscientious and having more motivation to decrease weight, or that the CPAP machine 
itself may improve tissue oxygenation and speed up metabolic processes, also leading to 
decreases in weight.  
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Despite the improvements in obesity among this subset of patients, the one-month 
follow-up shared similar results to the overnight period regarding insulin resistance, 
dropping slightly from 29.1 ± 3.0 kg/m2 to 28.9 ± 3.1 kg/m2 (25). However, the 21 
patients displayed greater decreases in aspartate aminotransferase levels, which w 
decreased from 35 ± 23 IU/mL to 27 ± 12 IU/mL. These changes were accompanied by 
significant decreases in serum triglycerides levels, 221 ± 107 mg/dL to 179 ± 123 mg/dL, 
as well as decreases in leptin levels, with data provided by 8 available patients, from 33 ± 
12 ng/mL to 23 ± 12 ng/mL.  
The data presented by Chin et al. suggest that regarding both short-term and long-term 
prognosis for patients afflicted with OSA, recurrent apnea and hypopnea events 
accompanied by intermittent hypoxia exacerbates hepatic deterioration. Based on the 
chemical marker of aminotransferases, OSA can further be implicated as a risk factor of 
NAFLD signifying hepatocellular damage following ischemia and reperfusion. Although 
not a conventional method of treating NAFLD, CPAP clearly improves the outcome of 
liver disease when used to treat OSA and has the potential to attenuate hepatocellular 
damage by removing any pathological factors caused by the presence of OSA. 
In addition, bariatric surgery also serves as another overlapping treatment for OSA and 
NAFLD.    Under the assumption that OSA mediated through obesity serves as a risk 
factor for NAFLD, decreasing a patient’s body mass index would then reduce the severity 
of both OSA and NAFLD postoperatively. This is supported in studies that separately 
show correlations involving decreases of BMI and decreased AHI (OSA) or lowered 
levels of aminotransferases (NAFLD) following the procedure. For example, Sarkosh et 
28 
 
al compiled a comprehensive search of 69 studies featuring 13,900 patients 
demonstrating the effectiveness of bariatric procedures in improving OSA. 
Preoperatively, the authors noted an average BMI of 48.6 kg/m2, with more than a fourth 
(26.24%) also affected by sleep disorder. The average AHI pre-op among these OSA 
patients was 51.52 events per hour (48). Postoperatively, the authors reported changes in 
both obesity and OSA, with a decrease in BMI and AHI of 17.9 kg/m2 and 38.2 
events/hour, respectively. As a result, these changes were reflected in patients’ average 
BMI, which was nearly measured as below obese (>30 kg/m2), as well as the average 
AHI, in which patients’ severe sleep apnea, defined as greater than 30 events/hour, 
improved to mild sleep apnea (5-14 events/hour) (48).  
The effects of bariatric surgery in treating NAFLD had similar results in treating OSA. 
For example, in a review conducted by Burza et al, the authors reported that among the 
3,570 obese patients surveyed, the 1,775 patients in the surgery group had decreased 
levels of aminotransferase compared to the 1,795 of the control group. While the 
aminotransferase levels in the control group of patients remained the same, the surgery 
group showed decreases from their baseline aminotransferase levels of 37 ± 23 U/L 
(AST) and 25 ± 14 U/L (ALT) during their 2- and 10-year follow-ups. The two-year 
follow-up demonstrated decreases in AST and ALT of 5 U/L and 15 U/L, respectively, 
while the 10-year follow-up showed an increase in AST of 1 U/L and a decrease in AST 
of 10 U/L (49). 
Thus far, OSA has been linked to the accumulation of fatty acids in the liver and the 
resulting inflammation of hepatic tissue stemming from recurrent nocturnal hypoxia as 
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well as additional causative factors such as insulin resistance, oxidative stress, and the 
abnormal imbalance of adipokines. These circumstances have all been known to correlate 
with NAFLD development and progression. Other studies have demonstrated that when 
directly measuring indexes and markers indicative of OSA and NAFLD, respectively, 
there have been correlations linking the former as a potential causative factor of the latter. 
In one study conducted by Cakmak et al, AHI along with other values accounting for 
OSA, such as oxygen desaturation index (ODI), lowest O2 saturation (LaSO2), and blood 
oxygen levels (SpO2), were measured against levels of aminotransferases for NAFLD 
(50). Consistent with OSA inducing the development of NAFLD, ALT levels and AST 
levels were 19% higher and 9.5% higher, respectively, in the OSA group as opposed to 
the control group.  
Furthermore, the severity of the OSA, as measured by the higher the number of events in 
AHI, correspondingly resulted in greater severity of NAFLD as measured by higher ALT 
and AST levels. This was reflected in patients with the severest forms of OSA, with 
AHI>30 having not only the greatest concentrations of liver enzymes (ALT of 27.7 ± 
12.6 U/L and AST of 23.4 ± 8.9 U/L) compared to mild OSA characterized by ALT and 
AST levels of 24.2 ± 10.6 U/L and 18.7 ± 5.5 U/L (50). Likewise, intermittent hypoxia 
also fluctuates in response to the severity of OSA. The patient subset with the most 
severe OSA (highest AHI) had proportionately low levels of mean ODI, LaSO2, and 
SpO2, measured as 57.2 ± 57.6 events/hour, 67.5 ± 11%, and 86.1 ± 7.9% respectively, 
compared to the values from the patient subset with mild OSA, which were 21.1 ± 5.1 
events/hour, 78.7 ± 8.9%, and 90.6 ± 2.9%, respectively (50). Therefore, lowered 
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numbers for oxygen saturation correlate with the higher aminotransferase levels, 
signifying that OSA-associated hypoxia does incites liver damage that induces 
progression of NAFLD.  
CROSS-TALK OF HYPOXIA WITH THE INNATE IMMUNE SYSTEM  
Hypoxia Inducible Factor as the Molecular Mediator between OSA and NAFLD 
In recent years, OSA and CIH have been referred to as communicating with the innate 
immune system and triggering inflammation through various molecular processes, which 
contribute to liver inflammation and damage (26). Much of these processes involve the 
upregulated activity of NF-κB and HIF. These two pro-inflammatory factors are involved 
in a positive feedback loop, recurrent in obese NAFLD patients who are also affected by 
intermittent hypoxia. The damage incited by prolonged oxygen deficiency is a result of 
adaptive cellular mechanisms, which triggers a mediator such as HIF to enact the 
appropriate metabolic response. The specific subunits of HIF that are responsible for 
cellular adaption to hypoxia are HIF-1𝛽, HIF-1𝛼, and HIF-2𝛼 (26). The normal cascade 
of chemical factors that begins with HIF eventually leads to oxygen transportation, 
angiogenesis, proliferation, and metabolism, all triggered with the purpose of reversing 
the effects of hypoxia.  
Naturally, any cellular process has a regulating force to prevent an over proliferation of 
function and in this scenario, safeguard the liver from severe damage. Yet, because these 
preventative factors, the iron-dependent enzymes prolyl hydrolases(PHDs) and factor-
inhibiting HIF (FIH) require a normoxic environment, the resulting process is the alluded 
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to positive feedback loop within a hypoxic environment (26). In the presence of oxygen, 
PHDs act in the cytoplasm to hydroxylate the HIF-𝛼 subunits, resulting in proteomic 
degradation by VHL-dependent ubiquitination. Likewise, FIH, of which oxygen is a 
cofactor for, normally hydroxylates asparaginyl residues in HIF-1𝛼 and HIF-2𝛼 when 
active, preventing interaction with various coactivators including P300 to form an active 
transcriptional complex (26). The two conditional pathways are detailed in Figure 6. 
Thus, in situations when oxygen is scarce, such as during OSA accompanied by CIH, the 
result is a lack of HIF inhibition, creating a perpetuating cycle in which HIF is 
continuously upregulated, consequently leading to liver inflammation and progression of 
NAFLD to NASH. 
Figure 6.  Oxygen-regulated HIF signaling. During conditions of normoxia, cellular 
oxygen sensors prolyl hydroxylases (PHD1–3) and factor inhibiting HIF (FIH) 
hydroxylate specific residues of HIFα subunits (HIF-1α and 2α for PHDs and HIF-1α for 
FIH). Hydroxylated HIFα is recognized by the von Hippel-Lindau (pVHL) E3 ubiquitin 
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ligase that polyubiquitinates HIFα, resulting in proteasomal degradation. During 
conditions of hypoxia, PHD and FIH activity are suppressed, stabilizing HIFα expression. 
HIFα then undergoes nuclear translocation where it dimerizes with its beta subunit. 
Figure taken from Wilson and Tennant (51). 
The other half of the hypoxia-driven positive feedback loop that contributes to liver 
damage involves NF-κB. While PHDs and FIH work post-transcriptionally under the 
presence of normoxic conditions, other transcriptional-level regulatory mechanisms are 
also active in causing hepatic injury. These regulatory elements are triggered in a state of 
inflammation, infection, or oxidative stress and involve communication with the HIF-1𝛼 
subunit. The mediators for this cross-talk between HIF and NF-κB are toll-like 
receptors(TLRs), which are located on the membranes of myeloid cells. Moreover, these 
factors are stimulated by lipopolysaccharides(LPS) and is followed by a signaling 
pathway involving NF-κB. Aside from generating an innate immune response, NF-κB is 
also responsible for induction of HIF-1𝛼 activity. Inflammation also results in higher 
levels of  TNF-𝛼, which was mentioned earlier as another inflammatory factor 
contributing to the onset of NASH. In addition, as with NF-κB, TNF-𝛼 also upregulates 
the expression of HIF-1𝛼 on innate immune cells. In the event of hypoxia, the 
upregulation of HIF begins a constant cycle that results in a heightened response of the 
innate immune system and inflammation. This leads to amplification of inflammatory 
factors such as NF-κB and TNF-𝛼, which feed back to the beginning of the loop by 
inducing increased levels of HIF. Therefore, these events demonstrate “cross-talk” 
between hypoxia and the innate immune system linking OSA and NAFLD.   
Insulin resistance as another characteristic hallmark regarding development of fatty liver 
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is further demonstrated in studies conducted by Taniguchi et al. The authors mention 
various enzymes involved in the regulation of hypoxia-induced hepatic HIF-2𝛼 that 
interfere with insulin sensitivity. Along with the HIF-1𝛼 subunit, HIF-2𝛼 is stabilized by 
three prolyl hydroxylase domain-containing protein isoforms, Phd1, Phd2, and Phd3 
(52). Phd3 is of interest given its effect on insulin receptor substrate-2 (Irs2), which 
serves as an important mediator for the anabolic effects of insulin. Diminished reception 
of Irs2 results in insulin resistance that contributes to the aggravation of the liver and 
progression of NAFLD.  
Furthermore, the authors engineered mice with every possible combination of Phd 
isoform and then proceeded to inject adenoviral Cre (adCre) to target and delete liver-
specific Phd genes. Of interest, the authors discovered that knocking out Phd3, also 
denoted as Egln3, coincided with improved insulin sensitivity and mitigation of diabetes 
type 1. Under normoxic conditions, Phd3 hydroxylates certain proline residues on HIF-
2𝛼, destabilizing the transcription factor. Therefore, deletion of Phd3 leads to 
stabilization of HIF-2𝛼, which results in the increase of Irs2 transcription and then 
insulin-stimulated Akt activation (52). Both HIF-2𝛼 and Irs2 are imperative for 
responding to insulin signaling, since the authors discovered that knocking out one or the 
other increased insulin resistance.  
Paradoxically, although knockout of hepatic Phd3 counteracted the loss of insulin 
sensitivity, the authors observed that increased expression of HIF-2𝛼 correlated with 
steatosis within mouse livers. Although knockout of Phd3 is required for an effect in 
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HIF-2𝛼, additional knockout of other Phd isoforms has an additive effect on HIF-2𝛼 and 
consequently, the severity of steatosis (52). This suggests that certain stressors, such as 
OSA, may increase levels of hypoxia-induced HIF-2𝛼, resulting in reciprocated levels of 
liver damage within NAFLD. The authors noted that mutant mice lacking various 
combination of Phd genes via adCre-deletion displayed heightened levels of hepatic 
triglycerides along with a prominent fatty liver. They speculated that the accumulation of 
fat in the livers of Phd-mutant mice is the collective result of three events as outlined 
below. 
The first involves the hypoxic upregulation of a gene encoding a glucose transporter, 
SLC2A1, or better known as Glut1 (52). Increased expression of SLC2A1 results in 
increased cellular uptake of glucose for various metabolic pathways. Mice lacking any 
one of the Phds displayed a 4.5-fold increase in SLC2A1 expression as well as a 42-fold 
increase in expression of SLC2A1 in mice missing both Phd2 and Phd3. The second 
concerns SREBP1a, which as previously stated  can be stimulated by hypoxia. Mice 
devoid of all three hepatic Phd genes exhibited a 15-fold increase in the normal 
expression of SREBP1a and thus, increased activity of lipogenesis (52). The third relates 
to the catabolic breakdown of fatty acid molecules. In mice with genetic combinations of 
Phd2 and Phd3 or Phd1, Phd2, and Phd3, the authors noticed decreased expression of 
CPT-1 by 50% and 83% in each respective combination (52).  Without CPT-1, there was 
failure of fatty acid conjugation to acyl carnitine for subsequent transfer inside the 
mitochondrial matrix through carnitine-acylcarnitine translocase (CAT), ultimately 
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rendering beta-oxidation impossible.  
The buildup of fat within the liver can then be explained through a combination of 
increased glucose uptake due to increased SLC2A1 expression, increased lipogenesis 
resulting from increased SREBP-1a expression, and decreased β-oxidation as supported 
by low CPT-1a levels. Thus, the authors demonstrate that the accumulation of liver fat 
responsible for the early stage of NAFLD can be traced back to the expression of HIF-2 
stemming from the key feature of OSA, CIH.   
Role of Toll-Like Receptors and Interaction with Hypoxia 
Briefly mentioned earlier, toll-like receptors or TLRs are components of the innate 
immune system that contribute to liver damage inherent of NAFLD. This often results 
from the imbalanced regulation of these innate immune receptors caused by a 
physiological stressor such as hypoxia. Once present, certain TLRs will form a complex 
with a coreceptor, lymphocyte antigen-96 or myeloid differentiation factor (MD2), which 
is a glycoprotein that anchors to both the extracellular domain of TLR as well as LPS. 
The TLR-LPS complex formed in a hypoxic environment is then able to initiate an 
inflammatory response. Patients afflicted by NAFLD are more sensitized to inflammatory 
responses related to hypoxia due to higher circulating LPS levels. The stronger response 
to LPS may be due to various factors in the bodies of NAFLD patients, including 
different species of gut microbiota, increases in gut permeability, as well as a fatty diet 
that contributes to obesity (26). 
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There are thirteen forms of TLRs, four of which are associated with pathogenesis and 
progression of NAFLD. However, only TLR4 is activated in response to hypoxic stress 
while serving as a mediator that initiates pathways leading to liver damage and disease. 
(70). The link between hypoxia and TLR4 was demonstrated by Kim et al through RNA 
interference and ChIP assays. To investigate this connection, the authors utilized CoCl2, a 
hypoxia mimetic, which was observed as enhancing TLR4 expression within 
macrophages.  Moreover, the hypoxic modulation of TLR activity seemed to be mediated 
through HIF-1α, given that knockout of HIF-1α by small interfering RNA (siRNA) 
downregulated hypoxia-induced and CoCl2-induced TLR4 activity while over-expression 
of HIF-1α had reciprocal responses for TLR4. ChIP assays further confirmed that low 
oxygen levels led to HIF-1α binding onto the TLR4 promoter region (53). Thus, HIF-1α 
is involved in the activation of the TLR4 receptor, although the exact mechanism of 
mediation is not well understood.  
Regardless of how this upregulation occurs, the effect of increased TLR4 levels induces 
more sensitive responses of macrophages to LPS, which then release elevated amounts of 
inflammatory factors, such as cyclooxygenase-2 (COX 2) IL-6, and interferon-inducible 
protein-10 (IP-10), which is a glycoprotein that anchors to both the extracellular domain 
of TLR as well as LPS. Kang et al demonstrated that the both the TLR and MD2 must be 
present and functioning on various liver cells such as Kupffer cells, stellate cells, and 
hepatocytes, to trigger inflammatory responses inciting liver damage (54).  
Kang et al manipulated genotypes of mice, creating populations deficient in either TLR 
or MD-2 as well as control genotypes. The mice were provided with a methionine 
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choline-deficient (MCD) diet to induce formation of the TLR-MD2 complex and 
stimulate hepatic inflammation. They observed that mice in the control group displayed 
accumulation of liver triglycerides, higher levels of ALT and perhaps most significantly, 
the presence of NASH accompanied by procollagen-I, transforming growth factor-1β, α-
smooth muscle actin, matrix metalloproteinase, which are indicative of liver fibrosis (54). 
On the other hand, mice with knockout of TLR or MD2 did not display the same severity 
in liver damage, nor did they exhibit the presence of NASH, the heightened levels of liver 
triglycerides, ALT, or markers indicating liver fibrosis (54). This trends provide more 
evidence of innate immune system cross-talk between components of OSA in relation to 
the formation of NAFLD, as carried out through formation of the TLR-MD2 complex.  
Hypothetically, during an episode of hypoxia mediated by HIF-1α, attachment of an LPS 
ligand to the TLR4-MD2 complex triggers a complex signaling cascade that generates 
multiple cellular responses. TLR4/MD2-mediated activation of MAP kinases and NF-κB 
leads to activation of the proinflammatory cascade and oxidative stress through the 
components of the NADPH complex (55). Activation of the inflammatory cascade and 
induction of reactive oxygen species are particularly relevant to NAFLD/NASH, since 
inflammatory cytokines, such as TNF- α activated by NF-κB, induces oxidative stress 
and contributes to liver inflammation in addition to insulin resistance, both characteristic 
of NAFLD progression to NASH. Thus, the sequence of events further supports a link 
between OSA as a causative risk factor of NAFLD.  
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Figure 7. Mechanism of NAFLD progression as induced by CIH. OSA increases 
intestinal permeability, modifies microbiota composition and increases microbiota 
diversity, subsequently leading to increased systemic lipopolysaccharide (LPS) levels. 
Consequently, these events lead to increased prevalence and severity of NASH. In the 
liver, this is accompanied by an increase in toll-like receptors (TLR-4) on hepatocytes, 
hepatic stellate cells and Kupffer cells. Figure taken from Aron-Wisnewsky and Pepin, 
2015 (56). 
 
Possibility of Hypoxia as a Protective Measure Against Liver Disease 
In controversy, HIF and by extension OSA may actually serve as a counteractive measure 
in which hypoxia inhibits adipogenesis and thus prevents NAFLD, rather than 
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contributing to the disease. As mentioned previously, during a hypoxic event the HIF-1𝛼 
subunit remains unhydroxylated at proline-564 without oxygen as a cofactor, preventing 
VHL-mediated ubiquitination and proteasomal degradation of HIF-1𝛼. Following 
stabilization, HIF-1𝛼 translocation to the nucleus is followed by dimerization with HIF-
1𝛽 to initiate gene expression (57). In relation to adipogenesis, upregulation of HIF 
results in the attenuation of specific genes involved in adipocyte differentiation. In other 
words, HIF and/or hypoxia mediates inhibition of these genes via DEC1/Stra13, which is 
one of the genes expressed following hypoxia-driven HIF coding for a family of 
transcription repressors. This family of transcription repressors are categorized as basic 
helix-loop-helix (bHLH) transcription factors and prevent expression of other 
transcription factors necessary for adipocyte differentiation. Among these are the 
CCAAT-enhancer-binding proteins (C/EBPs)- α, β, δ, and peroxisome proliferator-
activated receptor gamma 2 (PPAR-γ2) (58).  
Regarding these transcription factors, the expression of the DEC1 protein from the 
DEC1/Stra13 gene, represses gene expression through two methods: binding to enhancer 
E-box of PPARγ2 promoter regions as recognized by the CACGTG DNA sequence and 
blocking transcription, or by interaction with transactivators, including SBREPB-1C (59). 
In addition, DEC-1 binding to the PPARγ2 promoter is accompanied by rising levels of 
histone deacetyalse-1(HDAC-1). This suggests that aside from blocking the PPARγ2 
promoter region, DEC-1 in tandem with HDAC-1 adds another layer of regulation by 
deacetylating an ε-N-acetyl lysine amino acid on histones, subsequently allowing 
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histones to wrap DNA more tightly and preventing DNA transcription as well as PPARγ2 
expression. Ultimately, decreased activities of both SBREPB-1C and PPARγ2 results in 
decreased lipogenesis. Therefore, DEC-1 provides more protective effects against the 
buildup of fat within hepatic tissue as well as the onset of insulin resistance.  
Furthermore, the various transactivators of PPARγ2 are targets for gene repression by 
DEC-1 following upregulation by hypoxia. Among the C/EBP family, C/EBPβ is closely 
associated with adipogenesis, given its role as a transactivator for PPARγ2.  The 
development of preadipocytes supports this, as levels of C/EBPβ rapidly rise under 
induction from the adipogenesis hormones, 3- isobutyl-1-methylxanthine, 
dexamethasone, and insulin, collectively abbreviated as MDI (59). Western blotting 
analysis along with transient transfection and luciferase assay carried out by Park and 
Park has demonstrated that DEC1 interacts with C/EBPβ, as evidenced by the absence of 
bands accounting for mRNA from the authors’ Western blot and decreased activity from 
their  luciferase assay (59). However, the authors admit their understanding of hypoxia-
induced DEC1 is not complete, as they have ruled out through chromatin 
immunoprecipitation(ChIP) assays that DEC1 does not prevent binding of C/EBPβ to the 
PPARγ2 promoter region and restrict its transactivator function.  
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In relation to hypoxia, the same authors did discover an alternative pathway, independent 
of HIF expression and by extension, the DEC1/Stra13 gene. In this scenario, C/EBPβ is 
restricted from binding to the PPARγ2 promoter region and as consequence cannot assist 
in the transcription of the latter. This is attributed to hypoxia impairing function of 
glycogen synthase kinase-3 beta(GSK-3β). In normoxic conditions, C/EBPβ is permitted 
to bind on DNA following dual phosphorylation carried out by both ERK and GSK3β 
kinase (60) (61). In the event of hypoxia, GSK3β is blocked from entering the cell 
nucleus of preadipocytes and consequently, C/EBPβ is unable to interact with PPARγ2  
Intermittent Hypoxia (HIF) 
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Figure 8. Regulation of DEC1 by Intermittent Hypoxia. Intermittent hypoxia, 
mediated through HIF, upregulates the expression of DEC1. In turn, DEC1 then inhibits 
expression of both SBREPB-1C and PPARγ2, two genes involved in lipogenesis. 
Decreased lipogenesis then prevents the buildup of hepatic fat and development of 
NAFLD. Figure taken from Tahara and Tabata (62). 
and allow for expression of genes crucial to adipogenesis. Theoretically, this creates a 
paradoxical situation in which OSA is instead protective against NAFLD by preventing 
the buildup of fat as well as the onset of the disease. 
  PROGRESSION OF LIVER FIBROSIS INDUCED BY OSA 
Lox as a Biomarker of Liver Fibrosis 
The significance of detecting the early onset of fibrosis in patients with steatosis is 
crucial, given that prolonged liver scarring often terminates in cirrhosis and hepatic 
cancer. Many of the same biomarkers measured to detect NAFLD can also reveal later 
stages of liver disease, such as fibrosis (54). However, aminotransferase concentrations of 
AST and ALT and levels of pro- inflammatory factors including TNF-α only confirm the 
establishment of fibrosis within the liver. Higgins et al proposed a link between OSA-
induced HIF-1α and fibrosis, which they determined to be a fibrogenic enzyme known as 
lysyl oxidase (LOX). LOX is a secreted amine oxidase that catalyzes the formation of 
covalent cross-links between collagen fibers in the extracellular matrix (Figure 9). 
Increased LOX concentration in the liver are then used as an early warning to the buildup 
of excess hepatic fibrous connective tissue. Mesarwi et al support this in randomized 
clinical trials demonstrating that increased levels of LOX appear to be an early indicator 
of fibrosis. Their hypothesis was supported by three main findings. The first was that the 
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severity of OSA corresponded with the proliferation of fibrosis, that for every 5 events/h 
increase in AHI, there was approximately a 30% increase in the chance of developing 
liver fibrosis. The patients enrolled in their study with fibrosis had an average AHI of 
42.7 ± 30.2 events/h, compared to 16.2 ± 15.5 events/h for patients without it (64).  
 
Next, the authors also stated serum levels of LOX served as a sensitive and specific 
biomarker of liver fibrosis among obese patients with OSA. This was derived from the 
concentration of LOX as being measured higher in patients with established hepatic 
fibrosis, 84.64 ± 29.71 ng/mL, as opposed to 45.46 ± 17.16 ng/ mL among those without 
it, with each 10 ng/mL increase signifying a 2.3 fold increase in the chance of developing 
fibrosis.  
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Figure 9. Involvement of LOX in the progression of liver fibrosis. (A) LOX is 
increasingly secreted in hypoxic conditions and mediated through HIF. Increased LOX 
induces crosslinking of collagen fibers that contributes to fibrosis in a NAFLD-afflicted 
liver. (B) Intracellular LOXL2 regulates Snail1 or H3K4me3, repressing E-cadherin 
expression that eventually induces EMT. Figure taken from Moon et al (77). 
 
As a corollary to their first two reports, the authors concluded the expression of LOX is 
stronger in OSA patients whose livers show pathology of liver fibrosis. Their hypothesis 
was supported by their data describing patients with liver fibrosis as displaying a 6.7-fold 
increase in hepatic LOX mRNA levels. Similarly, mean serum LOX levels were lower in 
non-OSA patients, characterized by mean LOX levels of 52.36 ± 18.26 ng/mL, which 
rose to 70.75 ± 17.79 ng/mL among OSA patients. Moreover, the authors observed 
exposure of mice to intermittent air over a period of 4 weeks resulted in the 5.2-fold 
increase in the transcription of LOX mRNA compared to their control group.  
In addition, the authors highlighted that HIF-1α-driven epithelial-to-mesenchymal 
transition (EMT) may serve as mechanism in which obese OSA patients develop liver 
fibrosis. The importance of hypoxia-induced EMT is reflected in the conversion of 
epithelial cells to the mesenchymal phenotype (65). The precise cell type from which the 
mesenchymal cell arises from is currently unknown, although there are several 
candidates. Multiple hepatic cells within a NAFLD-afflicted liver are responsible for the 
uncontrolled deposition of extracellular matrix that manifests as liver fibrosis (65). Chief 
among these include hepatic stellate cells and myofibroblast cells. The exact mechanistic 
pathway from which these cells derive from under hypoxic stress is not yet fully 
understood, although various fibrogenetic studies provide insight into this topic.  
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Multiple sources have implicated hypoxia-driven expression of HIF-1α in association 
with LOX. For example, Erler et al carried out a luciferase assay in which they cloned the 
LOX promoter sequence into a pGL3-Basic (Promega) reporter plasmid to 
demonstrate the binding of HIF-1α to a hypoxia response element in the LOX promoter 
region (66). Similarly, Halberg et al pointed out that constitutive HIF-1α expression 
within adipose tissue consequently led to the overexpression of LOX as well as tissue 
fibrosis (67). Both cases are indicative of hypoxic stress as an early upstream initiator for 
potential hepatic tissue dysfunction regarding fibrosis mediated by LOX. Thus, the 
increase of LOX concentrations within the liver would then serve as an early warning to 
the buildup of excess hepatic fibrous connective tissue.  
Moreover, Mesarwi et al also mentioned the use of CPAP therapy as improving the 
pathology of liver fibrosis. As with NAFLD in lowering serum levels of 
aminotransferases, consistent use of CPAP corresponded with lowered levels of serum 
LOX. This was reflected in OSA patients who were not administered CPAP and saw no 
significant change in their mean serum LOX over 3 months, from 75.78 ± 17.77 ng/mL to 
72.38 ± 18.81 ng/mL. This was in contrast to OSA patients treated with CPAP therapy 
with greatly reduced mean serum LOX over the same period, from 65.73 ± 17.44 ng/mL 
to 45.24 ± 10.38 ng/mL (64). Therefore, LOX provides both a viable biomarker and a 
plausible biological mechanism for the progression of liver disease that is induced by 
OSA. 
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The Interaction of TGF-β1 With Hypoxia Induces EMT  
While EMT has been strongly implicated as a causative factor of liver fibrosis, the 
method through which it interacts with hypoxia is not well understood. The cytokine, 
TGF-β1, involved in hepatic inflammation and progression of NASH, may also explain 
the link between low oxygen levels and liver fibrosis in combination with ECM. TGF-β1 
is associated with essentially every progressive stage of liver disease, from the onset of 
NALFD and later NASH, eventually terminating in cirrhosis and hepatocellular 
carcinoma (68). This would suggest that following the early steatosis stage of liver 
disease, the body generates TGF-β1 that can then induce continuous inflammation with 
each subsequent stage of NAFLD, constantly renewing production of TGF-β1. 
Given that HIF is largely responsible for the physiological mechanisms generating 
pathology along the NAFLD spectrum, HIF could also be involved in some form of 
cross-talk with TGF-β1. Various studies establish the possibility of a signaling interaction 
between TGF-β1 and hypoxia culminating in fibrosis. In reference, Papakonstantinou et 
al created cell cultures of human fibroblasts to observe how hypoxia modulates TGF-β1 
and its influence on the production of gelatins and collagenases. The authors mention the 
association of matrix metalloproteinases (MMPs) with the generation of excess ECM 
comprising organ fibrosis. In addition, they also relate the regulation of MMPs by 
hypoxia and TGF-β1 (69). Similar to how loss of lipolysis and beta oxidation from 
dysfunctional PPAR-α and CPT-1 results in the accumulation of triglycerides within 
hepatocytes and the beginning of NAFLD, loss of MMPs results in the abnormal buildup 
of ECM signifying fibrosis development. With inhibition of specific gelatinases (MMP-2 
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and MMP-9) and collagenases (MMP-1 and MMP-13), the cell then loses its ability to 
degrade collagen and gelatin components of the ECM backbone, causing excessive ECM 
deposition. 
Despite its role in triggering liver pathogenesis, according to Alberti et al in a study of 
average cytokine levels among OSA patients, the serum concentrations of TGF-β1 do not 
actually increase in response to hypoxic conditions (69). Without increases in serum 
levels, this likely suggests an interaction between hypoxia and TGF-β1 regarding the 
induction of. This appears to hold true in the experimental studies of cell cultures and 
various fibrosis-inducing factors conducted by Papakonstantinou et al. They remarked 
that hypoxia alone seemed to have a protective effect regarding the onset of fibrosis, 
upregulating the expression of MMP-2 and MMP-9 and thus increasing enzymatic 
degradative activity (69). Yet given the circumstance of a hypoxia-related disease, such 
as OSA, release of TGF-β1 often accompanied diminished oxygen levels.  
The presence of TGF-β1 in a hypoxic cellular environment results in a 29% decrease in 
MMP-2 activity. Comparatively, the collagenase activities of both MMP-1 and MMP-13 
are decreased by 59% in the presence of both hypoxia and TGF-β1. In addition, tissue 
inhibitors of MMPs, or TIMPs also show a corresponding increase in the inhibiting effect 
of MMPs. The combination of hypoxia and TGF-β1 raised TIMP-1 activity by 79% (69). 
In contrast, TGF-β1 in the absence of hypoxia showed a modest increase in TIMP-1, only 
25%. Finally, the authors discovered that collagen secretion increased by a factor of 9 
under both hypoxic conditions and the presence of TGF-β1. In the normoxic control 
group, hypoxia and TGF-β1 alone accounted for a much lower increase of 4.5 times and 
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2 times, respectively, of the baseline activity. The data indicates a synergistic and 
necessary interaction between hypoxia and TGF-β1 that ultimately leads to the 
pathogenesis of fibrosis.  
Moreover, Roth and Copple hypothesized that communication between hypoxia and 
TGF-β1 also involves activation of the latter through regulation of the former. The 
authors mention the ability of hypoxic hepatocytes in converting TGF-β1 from a latent to 
an active state, dependent on HIF modulation (70). They believed the way this occurs 
involves hypoxic-upregulation of several MMPs and thrombospondin-1 (TSP-1). 
Hypoxia mediated through HIFs has been known to cause formation of microvesicles, 
such as matrix vesicles (MVs) (71). These MVs are believed to contain MMPs, especially 
the gelatinases MMP-2 and MMP-9 and the collagenase MMP-13, along with TGF-β1 in 
the form of a small latent complex (SLC). Upon release from the MV, the MMPs are then 
able to cleave a latency associated peptide (LAP) from the N-terminal region of the TGF-
β1 SLC, activating it (72). The process is demonstrated in Figure 10. Similarly, hypoxia 
also upregulates the expression of TSP-1, which then binds to the N-terminal sequence of 
the TGF-β1 SLC. Following this, the LAP is cleaved, creating a conformational 
rearrangement such that the LAP no longer confers latency on mature TGF-β1 (73) (74). 
These processes of activations are also in line with the earlier reference of hypoxia 
stimulating MMPs that would otherwise attenuate the onset of liver fibrosis were it not 
for the interaction with TGF-β1.  
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Figure 10. Potential profibrotic functions of hypoxia-inducible factors (HIFs) in 
hepatocytes and macrophages. Various hepatotoxicants generate hypoxia or induce 
upregulation of mediators activating HIFs in hepatocytes and M1-like inflammatory 
macrophages. HIFs in hepatocytes regulate MMPs, which is involved in converting latent 
transforming growth factor β1 (TGF-β1) to active TGF-β1. In macrophages, HIF-1α 
regulates production of VEGF, platelet-derived growth factor B (PDGF-B), and fibroblast 
growth factor 2 (FGF-2), promoting fibrosis by affecting hepatic stellate cell activation, 
proliferation, and collagen production. Figure taken from Roth and Copple (70). 
 
Returning to epithelial to mesenchymal transition, Copple proposed the importance of 
hepatocytes and bile duct epithelial cells as a source of myofibroblasts via hypoxic-
facilitated EMT. By exposing hepatocytes to 1% oxygen, there was an upregulation of α-
smooth muscle actin, vimentin, zinc finger protein SNAI1 (Snail), and fibroblast-specific 
protein-1 (FSP-1) consistent with proliferation of mesenchymal cell types (75). The 
hypoxic state also produced a corresponding change in epithelial cell-specific proteins, 
with decreases in zona occludens-1 and E-cadherin, suggesting a conversion from 
epithelial cell types. Both changes in structural proteins are representative of the fibrosis 
potentially caused by a hypoxia and by extension, OSA. Copple confirmed that HIF-1α is 
also a major driving force of liver fibrosis. This is referenced in previous studies 
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involving HIF-1α-deficient mice, in which levels of type I collagen mRNA/protein and 
activated fibroblasts were greatly reduced, resulting in less controlled deposition of 
collagen within the liver (76).  
With its association with hypoxia as evidenced by the studies of Papakonstantinou et al, it 
is plausible that the mechanism by which HIF-1α induces EMT involves TGF-β1. Copple 
incubated mice hepatocytes with SB-431542, a potent TGF-βI receptor inhibitor to 
determine its necessity in the hypoxic-signaling of hepatocyte EMT as compared to the 
control group untreated with SB-431542 (76). When exposed to one or the other, 1% 
oxygen or TGF-β1, mRNA levels of hepatic FSP-1 and Snail increased. However, in the 
presence of SB-431542, expression of FSP-1 and Snail were completely repressed in both 
scenarios. Consistent with Papakonstantinou et al, 1% oxygen within the hepatocyte cell 
culture triggered conversion of latent to active TGF-β1 without altering mRNA levels 
(76). Moreover, latent TGF-β1 added to hepatocyte cultures in 1% oxygen resulted in 
higher concentrations of FSP-1 and SNAIL whereas the normoxic conditions with latent 
TGF-β1 produced no such effect regarding FSP-1 and SNAIL.  
The data infers that hypoxia has the potential to produce liver fibrosis, directed through 
collaboration of HIF-1α with TGF-β1 to prompt EMT. The cross-talk between HIF-1α 
and TGF-β1 leads to the generation of fibrosis, which is then characterized by the 
heightened expression of several key regulatory proteins. Among these include 
transcription factors such as Snail. Upon stimulation by HIF-1α interacting with TGF-β1, 
Snail acts as a transcriptional repressor that binds to the E-box motifs within the E-
cadherin promoter region. This results in decreased synthesis of E-cadherin and 
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consequently, a decrease in adherens junctions that normally anchor epithelial cells to 
one another. Without adequate cell adhesion, hepatic cells are free to transition from 
linked, stationary epithelial cells to cells with migratory and invasive capabilities, such as 
fibroblast cells secreting unregulated amounts of collagen. The differentiation of a 
mesenchymal cell following transition from an epithelial cell into a fibroblast also occurs 
in response to increases in TGF-β1 induced by hypoxia. Following communication with 
HIF-1α, levels of the signal transducer FSP-1 rise, which is crucial for programming the 
mesenchymal cell to differentiate into the fibroblast phenotype. Other hypoxia-mediated 
changes that are unassociated with TGF-β1 involve cytoskeletal proteins, i.e. increases in 
α-SMA and vimentin as well as reorganization of F-actin into stress fibers that contribute 
to cell motility. Collectively, these alterations provide an explanation for how an OSA 
patient may be predisposed to liver fibrosis. It implicates hypoxia as a significant 
stimulus of hepatocyte EMT that is further detailed by HIF-1α communicating with TGF-
β1. A summary of liver fibrosis is given in Figure 11.  
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Figure 11. Mechanisms of hepatic fibrogenesis. Various cell types within the liver 
release proinflammatory factors contributing to hepatic inflammation. The activation of 
TIMP inhibits MMP activity, preventing degradation of the ECM. Consequently, ECM 
synthesis is then driven by secretion of TGF-β1, resulting in hepatic fibrosis following 
NASH. Figure taken from Liu et al (78). 
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CONCLUSION 
Obstructive sleep apnea and chronic intermittent hypoxia have been extensively 
investigated and established as factors in the pathogenesis and exacerbation of 
nonalcoholic fatty liver disease. NAFLD spans across many potential liver pathologies, 
including hepatic fat accumulation, hepatic tissue inflammation, fibrosis, and finally 
terminating in cirrhosis and hepatocellular carcinoma. As both diseases are linked by the 
circumstance of excessive fat stores, the global obesity epidemic will only serve to 
maintain prevalence of both diseases.  
There are various references to the associations of obesity and insulin resistance with 
OSA regarding the pathogenesis of NAFLD. Emerging evidence suggests that OSA may 
also account for the progression and development of NAFLD to NASH. This involves the 
upregulation of pro-inflammatory factors that lead to liver damage, such as NF-κB, and 
by transcription factors triggered by hypoxia, such as HIF. In addition, the generation of 
fibrosis is mediated by hypoxia and the interaction of HIF and TGF-β1.  
In order to prevent onset of either disease, obese patients predisposed to both OSA and 
NAFLD should make great efforts to implement consistent, vigorous exercise regiments 
in order to eliminate excess fat stores as well as incidence of insulin resistance. Separate 
studies have also presented bariatric surgery as a more immediate and viable option 
towards preventive measures on either OSA or NAFLD. However, there is a lack of 
literature involving effects of bariatric surgery that directly factor in OSA as a causative 
factor on NAFLD. Therefore, studies regarding this treatment option need to be further 
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explored by considering and measuring both OSA and NAFLD in the same clinical trials 
in regard to this causality.  
Moreover, there are limited studies accounting for the effectiveness of continuous 
positive airway pressure (CPAP) therapy in treating not only OSA, but also NAFLD. 
Future studies involving randomized placebo-controlled clinical trials should be carried 
out to truly assess the improvement of liver pathology through indirect use CPAP 
therapy. Furthermore, recognizing the potential mediators of inflammation also provide 
targets for pharmacological intervention. Testing within mice models might involve the 
administration of lipolysis inhibitors and antioxidants in order to attenuate the damage to 
the liver. In addition, prospective studies should explore the use of transgenic mice with 
knockout of genes involved in the OSA-driven causality of NAFLD, such as HIFs and 
NF-κB.  
In conclusion, as someone recently diagnosed with obstructive sleep apnea, exploring a 
causative relationship between OSA and nonalcoholic fatty liver disease has been eye-
opening. Understanding the potential consequences of not treating OSA to the fullest 
extent has led to a more faithful use of the CPAP machine, in order to avoid not only 
NAFLD but also cardiovascular and other life-complicating afflictions. As more evidence 
surfaces linking OSA as a causative factor of more severe and fatal diseases, OSA will be 
less overlooked as a disease and will be diagnosed sooner in potential patients. This will 
allow for earlier, more efficient treatment and hopefully in the future, provide a brighter 
outlook for many lives.  
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APPENDIX 
 
Table 1. Studies that measured liver enzymes and/or imaged liver in patients with 
OSA. Taken from Mirrakhimov & Polotsk, 2012 (35). 
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Table 2. Cross-sectional studies that examined liver biopsies in patients with OSA. 
Taken from Mirrakhimov & Polotsk, 2012 (35). 
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Table 3. Biochemical parameters, histological features and sleep characteristics of 
patients with non-alcoholic fatty liver disease (NAFLD) and controls. Taken from 
Bernsmeier et al. (79) 
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